Coageight (efmoroctocog alfa biosimilar)
/ AryoGen Pharmed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 29, 2026
Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
(clinicaltrials.gov)
- P=N/A | N=262 | Not yet recruiting | Sponsor: AryoGen Pharmed Co.
New trial • Hematological Disorders • Hemophilia • Hemophilia A • Rare Diseases
1 to 1
Of
1
Go to page
1